JP6657241B2 - Ｃｎｓ疾患を治療するための１−複素環イソクロマニル化合物およびアナログ - Google Patents
Ｃｎｓ疾患を治療するための１−複素環イソクロマニル化合物およびアナログ Download PDFInfo
- Publication number
- JP6657241B2 JP6657241B2 JP2017542401A JP2017542401A JP6657241B2 JP 6657241 B2 JP6657241 B2 JP 6657241B2 JP 2017542401 A JP2017542401 A JP 2017542401A JP 2017542401 A JP2017542401 A JP 2017542401A JP 6657241 B2 JP6657241 B2 JP 6657241B2
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolidine
- certain
- tert
- carboxylate
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCC*(*)c1c(*)c(*)c(*)c(*)c1C(*)(O)O* Chemical compound CCC*(*)c1c(*)c(*)c(*)c(*)c1C(*)(O)O* 0.000 description 21
- DJIQDHXAMYMRRC-ZCFIWIBFSA-N CC1(C)CN[C@@H](CO)C1 Chemical compound CC1(C)CN[C@@H](CO)C1 DJIQDHXAMYMRRC-ZCFIWIBFSA-N 0.000 description 2
- YDHXRLZTOOBMGJ-CHWSQXEVSA-N Fc1cc(CCO[C@H]2[C@@H]3NCCC3)c2cc1 Chemical compound Fc1cc(CCO[C@H]2[C@@H]3NCCC3)c2cc1 YDHXRLZTOOBMGJ-CHWSQXEVSA-N 0.000 description 2
- OOYKVQNGTZPJHK-UEWDXFNNSA-N C(C1)CN[C@@H]1C1OCCc2c1cccc2 Chemical compound C(C1)CN[C@@H]1C1OCCc2c1cccc2 OOYKVQNGTZPJHK-UEWDXFNNSA-N 0.000 description 1
- VTZBFZXHKISZSN-SMDDNHRTSA-N C(C1)CN[C@@H]1[C@@H]1OCCc2c1cc1OCOc1c2 Chemical compound C(C1)CN[C@@H]1[C@@H]1OCCc2c1cc1OCOc1c2 VTZBFZXHKISZSN-SMDDNHRTSA-N 0.000 description 1
- VTZBFZXHKISZSN-FZMZJTMJSA-N C(C1)CN[C@@H]1[C@H]1OCCc2c1cc1OCOc1c2 Chemical compound C(C1)CN[C@@H]1[C@H]1OCCc2c1cc1OCOc1c2 VTZBFZXHKISZSN-FZMZJTMJSA-N 0.000 description 1
- OOYKVQNGTZPJHK-CHWSQXEVSA-N C(C1)CN[C@H]1[C@@H]1OCCc2c1cccc2 Chemical compound C(C1)CN[C@H]1[C@@H]1OCCc2c1cccc2 OOYKVQNGTZPJHK-CHWSQXEVSA-N 0.000 description 1
- OOYKVQNGTZPJHK-OLZOCXBDSA-N C(C1)CN[C@H]1[C@H]1OCCc2c1cccc2 Chemical compound C(C1)CN[C@H]1[C@H]1OCCc2c1cccc2 OOYKVQNGTZPJHK-OLZOCXBDSA-N 0.000 description 1
- BMUURMGGFSSBHF-UHFFFAOYSA-N CC(C)(C)CNCCc1c(CCO)cccc1 Chemical compound CC(C)(C)CNCCc1c(CCO)cccc1 BMUURMGGFSSBHF-UHFFFAOYSA-N 0.000 description 1
- FMUVTLZEFAODFU-RVSXGSNBSA-N CC(C)(C)OC(CCC(CCC1)[C@@H]1C1OCCc2c1cccc2)=O Chemical compound CC(C)(C)OC(CCC(CCC1)[C@@H]1C1OCCc2c1cccc2)=O FMUVTLZEFAODFU-RVSXGSNBSA-N 0.000 description 1
- WFVZVMGMPBTVBW-VYRBHSGPSA-N CC(C)(C)OC(N(CCC1)[C@@H]1C(c(cc1)c(CCO)cc1F)O)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1C(c(cc1)c(CCO)cc1F)O)=O WFVZVMGMPBTVBW-VYRBHSGPSA-N 0.000 description 1
- HXGLTVHQMLKNPS-BHWOMJMDSA-N CC(C)(C)OC(N(CCC1)[C@@H]1C(c1c(CC(C)(C)O)cccc1)O)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1C(c1c(CC(C)(C)O)cccc1)O)=O HXGLTVHQMLKNPS-BHWOMJMDSA-N 0.000 description 1
- OTJGJTFFNJECOJ-NNJIEVJOSA-N CC(C)(C)OC(N(CCC1)[C@H]1C(C)(c(cc1)c(CO)cc1F)O)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@H]1C(C)(c(cc1)c(CO)cc1F)O)=O OTJGJTFFNJECOJ-NNJIEVJOSA-N 0.000 description 1
- GOFGCXUIGDLMLK-RZFJCUDFSA-N CC(C)(C)OC(N(CCC1)[C@H]1C(C)(c(cc1)c(COC2OCCCC2)cc1F)O)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@H]1C(C)(c(cc1)c(COC2OCCCC2)cc1F)O)=O GOFGCXUIGDLMLK-RZFJCUDFSA-N 0.000 description 1
- IKUVYMKKSFQTPT-AAFJCEBUSA-N CC(C)(C)OC(N(CCC1)[C@H]1C1OCCc2c1ccc(F)c2)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@H]1C1OCCc2c1ccc(F)c2)=O IKUVYMKKSFQTPT-AAFJCEBUSA-N 0.000 description 1
- JSQHGDKFPSXZNJ-ZIAGYGMSSA-N CC(C)(C1)CN[C@H]1[C@@H]1OCCc2c1cccc2 Chemical compound CC(C)(C1)CN[C@H]1[C@@H]1OCCc2c1cccc2 JSQHGDKFPSXZNJ-ZIAGYGMSSA-N 0.000 description 1
- JFEOGPCGHOYTAE-LSLKUGRBSA-N CC(C)(C1)OC([C@H]2NCCC2)c2c1cccc2 Chemical compound CC(C)(C1)OC([C@H]2NCCC2)c2c1cccc2 JFEOGPCGHOYTAE-LSLKUGRBSA-N 0.000 description 1
- LCUGETLBAITCCZ-GLXQMMQGSA-N FC(CO[C@H]1[C@H]2NCC2)c2c1ccc(F)c2 Chemical compound FC(CO[C@H]1[C@H]2NCC2)c2c1ccc(F)c2 LCUGETLBAITCCZ-GLXQMMQGSA-N 0.000 description 1
- XACMLRFYCQGELM-RYUDHWBXSA-N Fc1cc(CCO[C@@H]2[C@H]3NCC3)c2cc1 Chemical compound Fc1cc(CCO[C@@H]2[C@H]3NCC3)c2cc1 XACMLRFYCQGELM-RYUDHWBXSA-N 0.000 description 1
- XACMLRFYCQGELM-NWDGAFQWSA-N Fc1cc(CCO[C@H]2[C@H]3NCC3)c2cc1 Chemical compound Fc1cc(CCO[C@H]2[C@H]3NCC3)c2cc1 XACMLRFYCQGELM-NWDGAFQWSA-N 0.000 description 1
- DUVYLTNYKCCSSY-RYUDHWBXSA-N Fc1cc([C@@H]([C@H]2NCC2)OCC2)c2cc1 Chemical compound Fc1cc([C@@H]([C@H]2NCC2)OCC2)c2cc1 DUVYLTNYKCCSSY-RYUDHWBXSA-N 0.000 description 1
- DUVYLTNYKCCSSY-NWDGAFQWSA-N Fc1cc([C@H]([C@H]2NCC2)OCC2)c2cc1 Chemical compound Fc1cc([C@H]([C@H]2NCC2)OCC2)c2cc1 DUVYLTNYKCCSSY-NWDGAFQWSA-N 0.000 description 1
- DQZIITQAMQMBEX-KGLIPLIRSA-N N#Cc1cc(CCO[C@@H]2[C@@H]3NCCC3)c2cc1 Chemical compound N#Cc1cc(CCO[C@@H]2[C@@H]3NCCC3)c2cc1 DQZIITQAMQMBEX-KGLIPLIRSA-N 0.000 description 1
- DQZIITQAMQMBEX-ZIAGYGMSSA-N N#Cc1cc(CCO[C@H]2[C@@H]3NCCC3)c2cc1 Chemical compound N#Cc1cc(CCO[C@H]2[C@@H]3NCCC3)c2cc1 DQZIITQAMQMBEX-ZIAGYGMSSA-N 0.000 description 1
- DLSFBQCEKLDFJT-KBPBESRZSA-N N#Cc1cc([C@@H]([C@H]2NCCC2)OCC2)c2cc1 Chemical compound N#Cc1cc([C@@H]([C@H]2NCCC2)OCC2)c2cc1 DLSFBQCEKLDFJT-KBPBESRZSA-N 0.000 description 1
- MGMCOPSVEODZGV-CQSZACIVSA-N N#Cc1cc([C@H](C2=CCCN2)OCC2)c2cc1 Chemical compound N#Cc1cc([C@H](C2=CCCN2)OCC2)c2cc1 MGMCOPSVEODZGV-CQSZACIVSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N OCCc1ccccc1 Chemical compound OCCc1ccccc1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- MVUVVOWTNVWEFT-PZORYLMUSA-N [O-][NH+](CCC1)[C@H]1C1OCCc2c1ccc(F)c2 Chemical compound [O-][NH+](CCC1)[C@H]1C1OCCc2c1ccc(F)c2 MVUVVOWTNVWEFT-PZORYLMUSA-N 0.000 description 1
- AQQNZYSZKSCFCH-NUHJPDEHSA-N [OH3+2]CC(c1c(C[C@H]2NCC2)ccc(F)c1)F Chemical compound [OH3+2]CC(c1c(C[C@H]2NCC2)ccc(F)c1)F AQQNZYSZKSCFCH-NUHJPDEHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115064P | 2015-02-11 | 2015-02-11 | |
| US62/115,064 | 2015-02-11 | ||
| PCT/US2016/017539 WO2016130796A1 (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020018081A Division JP7023994B2 (ja) | 2015-02-11 | 2020-02-05 | Ｃｎｓ疾患を治療するための１－複素環イソクロマニル化合物およびアナログ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505205A JP2018505205A (ja) | 2018-02-22 |
| JP2018505205A5 JP2018505205A5 (enExample) | 2019-03-22 |
| JP6657241B2 true JP6657241B2 (ja) | 2020-03-04 |
Family
ID=55456908
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542401A Expired - Fee Related JP6657241B2 (ja) | 2015-02-11 | 2016-02-11 | Ｃｎｓ疾患を治療するための１−複素環イソクロマニル化合物およびアナログ |
| JP2020018081A Expired - Fee Related JP7023994B2 (ja) | 2015-02-11 | 2020-02-05 | Ｃｎｓ疾患を治療するための１－複素環イソクロマニル化合物およびアナログ |
| JP2022018580A Pending JP2022065050A (ja) | 2015-02-11 | 2022-02-09 | Ｃｎｓ疾患を治療するための１－複素環イソクロマニル化合物およびアナログ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020018081A Expired - Fee Related JP7023994B2 (ja) | 2015-02-11 | 2020-02-05 | Ｃｎｓ疾患を治療するための１－複素環イソクロマニル化合物およびアナログ |
| JP2022018580A Pending JP2022065050A (ja) | 2015-02-11 | 2022-02-09 | Ｃｎｓ疾患を治療するための１－複素環イソクロマニル化合物およびアナログ |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9856238B2 (enExample) |
| EP (2) | EP4046995B1 (enExample) |
| JP (3) | JP6657241B2 (enExample) |
| KR (1) | KR102601972B1 (enExample) |
| CN (2) | CN111925360B (enExample) |
| AU (1) | AU2016219253C1 (enExample) |
| CA (1) | CA2976095C (enExample) |
| CY (1) | CY1125198T1 (enExample) |
| DK (1) | DK3256466T3 (enExample) |
| EA (1) | EA201791804A1 (enExample) |
| ES (2) | ES2911910T3 (enExample) |
| HU (1) | HUE058698T2 (enExample) |
| IL (1) | IL253914B (enExample) |
| MX (2) | MX392664B (enExample) |
| MY (1) | MY188160A (enExample) |
| NZ (1) | NZ735011A (enExample) |
| PH (1) | PH12017501422A1 (enExample) |
| PL (1) | PL3256466T3 (enExample) |
| PT (1) | PT3256466T (enExample) |
| SG (2) | SG10201806809QA (enExample) |
| UA (1) | UA122222C2 (enExample) |
| WO (1) | WO2016130796A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102623321B1 (ko) * | 2015-02-11 | 2024-01-09 | 선오비온 파마슈티컬스 인코포레이티드 | 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체 |
| CN111925360B (zh) * | 2015-02-11 | 2024-03-22 | 赛诺维信制药公司 | 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 |
| JP7187437B2 (ja) * | 2016-07-29 | 2022-12-12 | サノビオン ファーマシューティカルズ インク | 化合物および組成物ならびにそれらの使用 |
| EP3490607A4 (en) | 2016-07-29 | 2020-04-08 | Sunovion Pharmaceuticals Inc. | COMPOUNDS AND COMPOSITIONS, AND USES THEREOF |
| EA202090180A1 (ru) | 2017-06-30 | 2020-05-26 | Чейс Терапьютикс Корпорейшн | Композиции nk1-антагониста и способы лечения депрессии |
| SG11202000669VA (en) | 2017-08-02 | 2020-02-27 | Sunovion Pharmaceuticals Inc | Isochroman compounds and uses thereof |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| KR20210139376A (ko) | 2019-03-14 | 2021-11-22 | 선오비온 파마슈티컬스 인코포레이티드 | 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물 |
| US12077546B2 (en) | 2021-04-10 | 2024-09-03 | Sumitomo Pharma Co., Ltd. | Bicyclic pyridine derivative |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3438995A (en) | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
| US5621133A (en) | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US5238939A (en) * | 1990-05-25 | 1993-08-24 | Akzo N.V. | Isochromane derivatives |
| IE73232B1 (en) * | 1990-05-25 | 1997-05-21 | Akzo Nv | Isochromane derivatives |
| DE69912279T2 (de) | 1998-06-30 | 2004-07-29 | Eli Lilly And Co., Indianapolis | 5-ht1f agonisten |
| SE9902267D0 (sv) * | 1999-06-16 | 1999-06-16 | Astra Ab | New compounds |
| RU2004117211A (ru) * | 2001-11-08 | 2005-03-27 | Сепракор, Инк. (Us) | Способы лечения депресии и других рассстройств цнс с использованием энантиомерно обогащшенных десметил-и дидесметилметаболитов циталопрама |
| BRPI0515830A (pt) * | 2004-12-21 | 2008-08-05 | F Hoffmann La Roche | derivados de cromano e usos dos mesmos no tratamento de distúrbios do sistema nervoso central |
| BRPI0707258A2 (pt) * | 2005-01-27 | 2011-04-26 | Hoffmann La Roche | uso de 2-imidazóis para o tratamento de distúrbios de cns |
| PE20061297A1 (es) | 2005-04-22 | 2006-12-24 | Wyeth Corp | Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c |
| KR101103118B1 (ko) | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물 |
| KR102074089B1 (ko) * | 2009-12-04 | 2020-02-05 | 선오비온 파마슈티컬스 인코포레이티드 | 다환형 화합물 및 이의 사용 방법 |
| US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| AR090557A1 (es) * | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
| WO2014106238A1 (en) * | 2012-12-31 | 2014-07-03 | Fang, Qun, Kevin | Heterocyclic compounds and methods of use thereof |
| CN111925360B (zh) * | 2015-02-11 | 2024-03-22 | 赛诺维信制药公司 | 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 |
-
2016
- 2016-02-11 CN CN202010607608.6A patent/CN111925360B/zh active Active
- 2016-02-11 EP EP22166538.3A patent/EP4046995B1/en active Active
- 2016-02-11 WO PCT/US2016/017539 patent/WO2016130796A1/en not_active Ceased
- 2016-02-11 ES ES16708262T patent/ES2911910T3/es active Active
- 2016-02-11 KR KR1020177025290A patent/KR102601972B1/ko active Active
- 2016-02-11 ES ES22166538T patent/ES2967643T3/es active Active
- 2016-02-11 DK DK16708262.7T patent/DK3256466T3/da active
- 2016-02-11 EA EA201791804A patent/EA201791804A1/ru unknown
- 2016-02-11 PL PL16708262T patent/PL3256466T3/pl unknown
- 2016-02-11 SG SG10201806809QA patent/SG10201806809QA/en unknown
- 2016-02-11 CN CN201680018639.XA patent/CN107531674B/zh active Active
- 2016-02-11 NZ NZ735011A patent/NZ735011A/en not_active IP Right Cessation
- 2016-02-11 MX MX2020001157A patent/MX392664B/es unknown
- 2016-02-11 US US15/041,852 patent/US9856238B2/en active Active
- 2016-02-11 HU HUE16708262A patent/HUE058698T2/hu unknown
- 2016-02-11 JP JP2017542401A patent/JP6657241B2/ja not_active Expired - Fee Related
- 2016-02-11 EP EP16708262.7A patent/EP3256466B9/en active Active
- 2016-02-11 MX MX2017010363A patent/MX371404B/es active IP Right Grant
- 2016-02-11 SG SG11201706515QA patent/SG11201706515QA/en unknown
- 2016-02-11 AU AU2016219253A patent/AU2016219253C1/en not_active Ceased
- 2016-02-11 PT PT167082627T patent/PT3256466T/pt unknown
- 2016-02-11 UA UAA201708945A patent/UA122222C2/uk unknown
- 2016-02-11 CA CA2976095A patent/CA2976095C/en active Active
- 2016-02-11 MY MYPI2017702923A patent/MY188160A/en unknown
-
2017
- 2017-08-08 IL IL253914A patent/IL253914B/en unknown
- 2017-08-09 PH PH12017501422A patent/PH12017501422A1/en unknown
- 2017-11-21 US US15/819,372 patent/US10336732B2/en active Active
-
2019
- 2019-05-06 US US16/403,698 patent/US11192885B2/en active Active
-
2020
- 2020-02-05 JP JP2020018081A patent/JP7023994B2/ja not_active Expired - Fee Related
-
2021
- 2021-10-29 US US17/452,786 patent/US20220185799A1/en not_active Abandoned
-
2022
- 2022-02-09 JP JP2022018580A patent/JP2022065050A/ja active Pending
- 2022-05-20 CY CY20221100352T patent/CY1125198T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6657241B2 (ja) | Ｃｎｓ疾患を治療するための１−複素環イソクロマニル化合物およびアナログ | |
| JP6561128B2 (ja) | Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ | |
| EP4043460B1 (en) | Antiproliferation compounds and uses thereof | |
| AU2018312559A1 (en) | Isochroman compounds and uses thereof | |
| HK40078692A (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| HK40078692B (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| HK40042391A (en) | 1-heterocyclyl isochromanyl compounds and analogus for treating cns disorders | |
| HK1241876A1 (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| HK1241876B (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| EA046724B1 (ru) | Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс | |
| BR112017017354B1 (pt) | Composto e seu uso, composição, processo para preparar um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A525 Effective date: 20171013 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190208 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190208 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191114 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200107 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6657241 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |